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Summary
Objectives: The kinetics of three serological markers (IgM, IgA, and IgG) in serum, saliva, and
urine samples from adult patients with primary or secondary dengue infection were studied.
Design: Serum, saliva, and urine samples were collected from 22 patients with clinical and
confirmed dengue 3 virus infection during the outbreak in Havana City in 2001. They were tested
by capture IgM (MAC-ELISA), IgA (AAC-ELISA), and IgE (EAC-ELISA) and IgG ELISA inhibition method
(EIM) to detect specific dengue antibodies.
Results: Similar kinetics were observed in IgM, IgA, and IgG antibodies in saliva and IgA and IgG in
urine samples from secondary cases compared with kinetics in serum samples, although the
values were lower. No IgG antibody was detected in saliva and urine samples in primary cases and
IgM antibody was not detected in urine samples from either primary or secondary infection. All
secondary cases were positive for IgG in saliva and urine samples at day 7. The kinetics of specific
IgE antibodies in primary and secondary cases were different.
Conclusions: The kinetics of three serological markers (IgM, IgA, and IgG) in serum, saliva, and
urine samples from adult patients with primary or secondary dengue 3 virus infection were
studied for the first time, showing its behavior and usefulness in dengue virus diagnosis. The
specific IgE could play a role as a serological marker in secondary infections.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.* Corresponding author. Tel.: +53 7 2020450; fax: +53 7 2046051.
E-mail address: svazquez@ipk.sld.cu (S. Va´zquez).
1201-9712/$32.00 # 2006 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2006.05.005Introduction
Dengue virus is a mosquito-borne virus of the Flaviviridae
family. The four serotypes (dengue 1, 2, 3, and 4) arePublished by Elsevier Ltd. All rights reserved.
Kinetics of antibodies in dengue 3 virus infections 257transmitted to humans through the bite of infected mosqui-
toes, Aedes aegypti and Aedes albopictus being the main
vectors. Dengue virus infection causes a spectrum of syn-
dromes ranging from mild febrile illness to classical dengue
fever and severe and fatal hemorrhagic disease.1 Inapparent
infection is very common.2
Specific dengue IgM detection in serum by ELISA has
become one of the most important and useful methods of
dengue diagnosis.3—5 Serum is the preferred sample for
serological studies, but its collection is difficult in infants
and small children and in field conditions.6 The usefulness of
saliva for dengue diagnosis has been partially evaluated by
others,7,8 but we know of no report of the use of urine
samples in dengue diagnosis.
To define the usefulness of saliva and urine for dengue
diagnosis and to study the kinetics of specific dengue anti-
bodies, the presence of dengue IgM, IgA, and IgG was deter-
mined in serum, saliva, and urine collected from dengue 3
virus infected cases during the Havana outbreak of 2001—
2002.9,10 The total and specific dengue IgE antibodies
response in serum samples were also studied, in view of
previous reports of the increase of this antibody in dengue
patients.11—13
Materials and methods
Clinical samples
A total of 411 clinical samples of serum, saliva, and urine (137
for each kind of sample) were collected from 22 hospitalized
and confirmed adult cases of dengue at ‘‘Pedro Kourı´’’ hos-
pital. Dengue 3 virus was isolated and/or detected by RT-PCR
in all patients. The samples were collected during the acute
illness (from day 3 to 8 and 20 days later) early in the
morning. Serum was obtained by conventional methods.
All samples (serum, saliva, and urine) were kept at 20 8C
until study. Informed consent was obtained from all patients
and subjects. This group of patients constituted 11 women
and 11 men aged between 21 and 58 years (average: 36
years). Cases were classified as dengue fever (DF) or dengue
hemorrhagic fever (DHF) according to the PAHO/WHO Guide-
lines for the Control and Prevention of Dengue and Dengue
Hemorrhagic Fever in The Americas.14
Viral antigens
The antigens used in the serological studies were dengue 1
(Hawaii strain), dengue 2 (New Guinea C strain), dengue 3 (H-
87 strain), and dengue 4 (H-241 strain) prepared in mouse
brains and extracted by acetone—sucrose extraction techni-
que.15
Capture IgM (MAC-ELISA), IgA (AAC-ELISA), and
IgE (EAC-ELISA) specific dengue antibodies by
ELISA
In-house tests with similar protocols to MAC, AAC, and EAC
ELISA were used.5,16,17 Briefly, NUNC MaxiSorp plates were
coated with goat IgG anti-human IgM (Sigma), goat IgG anti-
human IgA (ImmuneAssay Center, Havana, Cuba), and goat
IgG anti-human IgE (Sigma). After blocking, 50 mL of 1/20serum dilution to detect IgM and IgA dengue antibodies and
1/5 serum dilution to detect IgE dengue antibodies in phos-
phate-buffered saline (PBS) plus 0.5% bovine serum albumin
(BSA) were added. Saliva and urine samples (50 mL/well)
without dilution were used. Positive (duplicate) and nega-
tive (quadruplicate) controls were included in each test.
Samples were incubated for two hours at room temperature
for IgM and IgA and at 37 8C for IgE antibody detection. An
antigen mixture of the four dengue serotypes was added.
After overnight incubation, 50 mL of human conjugate IgG
anti-dengue diluted 1/5000 was added. Orthophenilenedia-
mine (OPD) and hydrogen peroxide were used as substrate.
The reaction was stopped and the plates were read at
492 nm.
The optical density ratio (OD ratio) = P/N was calculated
in all samples. P represents the OD of each serum sample and
N represents the OD mean of the negative control, calcu-
lated with the four OD values. The negative controls were
pools of sera, saliva, and urine from individuals without
dengue background and negative to IgM, IgA, IgE, and IgG
antibodies.
All samples with an OD ratio 2 were considered positive
by MAC and AAC ELISA; for EAC ELISA, an OD ratio 1.4 was
considered positive.5,16,17
Total IgE antibody
To detect total IgE antibody the UMELISA IgE system devel-
oped by the ImmunoAssay Center, Havana, Cuba was used.
The test was performed according to the manufacturer’s
instructions. A total IgE concentration greater than or equal
to 150 IU/mL was considered positive in serum samples from
adult patients.
ELISA inhibition method (EIM) to detect IgG anti-
dengue
The ELISA inhibition method (EIM) was followed as previously
described.18,19 Briefly, polystyrene plates (Costar No. 3591)
were adsorbed with human anti-dengue IgG; after blocking,
dengue 3 antigen previously diluted 1/40 in PBS plus 0.05%
Tween-20 was added in each well. Serum samples diluted
from 1/20 to 1/40 960 and saliva and urine diluted (1/2—1/
512) and undiluted were tested. Volumes of 100 mL of each
sample were added. Human IgG anti-dengue peroxidase
conjugate diluted 1/3000 in PBS plus 0.05% Tween-20 and
2% fetal bovine serum were added. Substrate containing OPD
was added. The reaction was stopped after 30 minutes incu-
bation. The test was read at 492 nm. The inhibition percent
was calculated as:
Inhibition% ¼ 1 OD sample
OD negative control
  
 100
The antibody titer for each sample was considered as the
highest dilution with a percentage of inhibition 50. An IgG
antibody titer <20 in the acute serum (collected at days 3 or
4 of fever onset) and <1280 in the early convalescent serum
(collected at days 7 or 8 of fever onset) were taken as
evidence of a primary infection. By contrast, an IgG antibody
titer20 in the acute serum (collected at days 3 or 4 of fever
onset) and 1280 in early convalescent serum (collected at
258 S. Va´zquez et al.days 7 or 8 of fever onset) with a four-fold or higher increase
of the antibody titer or titer10 240 in any serumwere taken
as evidence of a secondary infection.16,19
Capture IgG ELISA (GAC-ELISA)
An IgG capture ELISA test (GAC-ELISA) was employed to
detect IgG antibody in urine samples. A protocol similar to
the MAC-ELISA test5,16 with minor modifications was used.
The NUNC MaxiSorp plates were coated with 100 mL per well
containing 10 mg/mL of goat IgG anti-human IgG (Sigma) and
urine samples were used without dilution (50 mL/well). Posi-
tive and negative controls in each test were included. All
samples with an OD ratio 2 were considered positive.
Results
Type of infection: primary or secondary
From the total of 22 cases, 19were classified as dengue fever
(DF); four of themwere primary infections and 15 secondary
infections (Table 1). The last three cases were classified as
dengue hemorrhagic fever (DHF) and all of them were
secondary infections (patients 20—22 in Table 1). The com-
parative study was performed between the different
types of samples in cases of primary and secondary dengue
infection.Table 1 Classification of 22 dengue infection patients into
primary or secondary cases by EIM
Case number Antibody titers a Classification
1 <20/20 Primary
2 <20/<20 Primary
3 <20/<20 Primary
4 <20/40 Primary
5 320/5120 Secondary
6 20/10 240 Secondary
7 40/40 960 Secondary
8 80/40 960 Secondary
9 160/40 960 Secondary
10 1280/20 480 Secondary
11 160/20 480 Secondary
12 40/40 960 Secondary
13 80/20 480 Secondary
14 20/10 240 Secondary
15 320/20 480 Secondary
16 40/5120 Secondary
17 320/40 960 Secondary
18 20/10 240 Secondary
19 160/2560 Secondary
20 640/10 240 Secondary
21 40/20 480 Secondary
22 320/10 240 Secondary
a Primary case: IgG antibody titer in acute serum <20 (days 3 or
4 after onset) and in early convalescence<1280 (days 7 or 8 after
onset). Secondary cases: IgG antibody titer 20 in acute serum
(days 3 or 4 of fever onset) and early convalescence1280 (days 7
or 8 of fever onset) with a four-fold or higher increase in the
antibody titer or titer 10 240 in any serum.Kinetics of IgM, IgA, and IgG antibodies in serum,
saliva, and urine samples
Figure 1 shows the kinetics of specific dengue IgM, IgA, and
IgG antibodies in serum, saliva, and urine samples according
the type of infection (primary or secondary).
Primary cases: for these cases it was only possible to
obtain serum samples between three and seven days follow-
ing onset of symptoms.
An increase of dengue IgM antibodies was observed in
serum and saliva of patients with a primary infection
(Figure 1A and C). In serum, the increase of IgM was first
detected at day 4 with an OD mean ratio  standard devia-
tion of 2.83  0.86. The highest values were observed at day
6 (15  1.56). In saliva, this increase was on day 5
(2.29  0.99) and the maximum value was on day 7
(4.9  1.25). No IgM antibody was detected in urine samples
(Figure 1E). In addition, slow increments in the ODmean ratio
values of IgA antibodies in serum, saliva, and urine were
observed. IgA in serum showed values from 1.38  0.42 to
6.73  3.81 (Figure 1A). The OD mean ratio fluctuated from
1.34  0.48 to 1.91  0.80 in saliva (Figure 1C) and from
1.10  0.13 to 2.90  0.75 in urine samples (Figure 1E).
Positive IgM and IgA antibody values in serum were first
detected on average at days 4.25 and 5.5, respectively, after
onset of fever. Positive IgM in saliva was detected on average
at day 5.75. Specific IgG was first detected in serum at day 7
(geometric mean titer = 30). No IgG antibody was detected
in saliva and urine samples.
Secondary cases: in serum samples from secondary cases,
the abrupt appearance of IgM antibodies was observed at day
3 (2.09  1.94) being maximum at day 7 (11.36  3.00). IgA
and IgG antibodies increased slowly during the first days of
the study. Values for IgA ranged from 1.24  0.47 (day 3) to
7.07  3.51 (day 7) (Figure 1B). The GMT of IgG titer fluc-
tuated from 15 (day 3) to 15 343 (day 8).
IgM, IgA, and IgG immunoglobulins in saliva (Figure 1D) and
IgA and IgG in urine samples (Figure 1F), showed similar
kinetics although the values obtained were lower than those
observed in sera. The IgM OD mean ratio in saliva showed
values of 1.79  0.48 (day 3) to 7.10  4.07 (day 6) while IgA
values were 1.39  0.31 (day 3) and 3.15  1.79 (day 7).
In urine samples, no IgM antibody was detected, IgA values
ranged from1.13  0.13 (day 3) to 5.29  2.45 (day 8), and IgG
values were from 0.93  0.1 (day 3) to 6.07  4.03 (day 7).
Positive IgM and IgA antibody values in serum were first
detected on average at days 4.1 and 4.8, respectively; in
saliva these were at 4.4 and 5.7 days after onset. In urine
samples, positivity to IgA was at 6.3 days after onset. In
secondary infection, the IgM response in serum and saliva
samples was always higher than the IgA response. The posi-
tivity to IgG in saliva was at 5.3 days after onset.
In undiluted urine samples, only 11/18 (61.1%) of the
secondary cases were positive by EIM (average 6.81 days).
Urine samples were also assayed by GAC-ELISA test and most
of them were IgG positive between 6 and 7 days (average
5.78) after onset with IgG values of 3.16  2.18 and
6.07  4.03, respectively (primary y-axis in Figure 1F).
The IgG antibody was detected in saliva and urine samples
when IgG titers in serum were 1280 or higher. The OD mean
ratio values of all immunoglobulins studied decreased after
day 20 of fever onset in secondary cases.
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Figure 1 Kinetics of IgM, IgA, and IgG dengue virus antibodies in serum samples (A primary and B secondary cases), in saliva samples
(C primary and D secondary cases) and in urine samples (E primary and F secondary cases). The principal y-axis shows the IgM and IgA
optical density (OD) mean ratio + standard deviation (SD). The secondary y-axis shows the geometric mean titer (GMT) + SD of the IgG
antibodies in serum and saliva samples (A, B, C, and D). The IgG antibodies in urine samples detected by GAC-ELISA assay are shown as
OD mean ratio + SD (E and F principal y-axis; n = the total from each type of sample tested by day).Comparison of percentages of positives to IgM,
IgA, and IgG antibodies in serum, saliva, and
urine samples from patients with primary and
secondary dengue infection
Figure 2 shows the percentage of cases (by day of illness) with
positive IgM (A primary and B secondary cases), IgA (C primary
and D secondary cases), and IgG (E primary and F secondary
cases) in serum, saliva, and urine samples.
By day 5, 100% of both primary and secondary cases had a
positive IgM response in serum. In saliva, 100% of primary and
secondary cases showed a positive IgM at days 6 and 7,
respectively, however a large number of patientswere already
positivebyday5 (75and83.3%).A 100%positive IgA response in
serum in primary and secondary cases was observed at day 7
(Figure 2C and D). All secondary cases were positive to IgG in
saliva and urine samples at day 7 (Figure 2F).
Kinetics of specific and total IgE antibodies in
serum samples of patients with a primary or
secondary infection
Values of specific and total IgE in serum samples are shown in
Figure 3 (A primary cases and B secondary cases). An increase
in the OD mean ratio values of specific IgE was observed at
day 7 (1.7  0.20) in primary cases and at day 5
(1.45  0.507) in secondary cases being highest at day 8
(2.28  0.823). Most secondary cases showed a positiveanti-dengue specific IgE response around day 6 (average,
day 5.9). The comparative analysis between primary and
secondary specific IgE using the t-test showed no significant
difference ( p > 0.05).
In primary cases the IgE total mean values were between
1686 IU/mL (day 3) and 770 IU/mL (day 7). In secondary cases
the total IgE showed a range of values between 687 UI/mL
(day 3) and 588 IU/mL (day 8) after outbreak.
Discussion
The presence of antibodies in saliva and urine has been
studied in rubella,20 hepatitis A,21,22 and hepatitis C23 among
others; but there are few reports on dengue IgM, IgA, and IgG
detection in saliva samples7,8,24 and we found none employ-
ing urine samples.
The kinetics of IgM, IgA, and IgG antibodies showed a
similar pattern in saliva and serum samples in both primary
and secondary cases. Despite the similarity in the kinetic
profile of the antibody response, the IgM and IgA OD values
and the geometric mean titer of IgG antibodies were lower in
saliva than in serum samples. The IgA values were lower than
IgM both in serum and saliva. Similar results in serum have
been found by other authors.25,26
Urine is a body fluid with low but measurable concentra-
tions of immunoglobulins derived from plasma either through
the kidney or by transudation into the lower renal tract.21,27
It has been postulated that large macromolecules such as IgM
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Figure 2 Percentage of positives in serum, saliva, and urine samples to IgM antibody (A primary and B secondary cases), to IgA
antibody (C primary and D secondary cases), and to IgG antibody (E primary and F secondary cases) at different days after outbreak.antibodies cannot pass through the glomerular filter under
normal conditions; however, the IgM protein in its monomeric
form has been detected in some viral infections.21,22,28 In our
study, specific IgM was not detected in urine samples. In
contrast, IgA antibodies were detectable in both primary and
secondary cases showing a similar pattern as in serum and
saliva samples. The IgA OD mean values were slightly higherFigure 3 Kinetics of specific and total IgE antibodies in serum samp
the IgE specific OD (mean ratio + SD). The secondary y-axis shows a plo
the serum samples tested by day.in urine than in saliva in both types of infection. These results
could be due to the presence of non-specific IgA secretions28
that could be competing with the anti-dengue IgA of saliva in
the capture ELISA.
EIM is an ELISA test standardized to detect dengue IgG
antibodies in serum samples with high sensitivity and speci-
ficity, and it has been used to classify into primary or sec-les (A primary and B secondary cases). The principal y-axis shows
t of the total IgE expressed in IU/mL (mean + SD); n = the total of
Kinetics of antibodies in dengue 3 virus infections 261ondary infections.9,16,17,19,29—31 In the present study, EIM was
employed to detect dengue IgG antibody in saliva and urine
samples using similar conditions as in serum samples. IgG
antibodies were detected in saliva in all secondary cases
(average at 5.3 days), however, in only 11 of 18 secondary
cases (average 6.81 days) in urine samples.
The GAC-ELISA test has been used to detect IgG antibodies
in urine samples from different viral infections with good
results.32—34 The GAC-ELISA test was included in this study in
order to determine if the non-detection of IgG in all urine
samples was due to the absence of these antibodies or a low
sensitivity of EIM in this type of sample. GAC-ELISA detection
showed a 100% positivity in secondary cases at day 7 after
onset. The sensitivity of the EIM was lower (61%) compared
with GAC-ELISA in the urine samples and also the average day
of detection of IgG antibodies was later. It could be useful to
consider different standards for EIM when using this type of
sample in order to increase the sensitivity.
IgM detection in sera is still the preferred marker for the
early serological diagnosis of dengue infection. IgM detection
in saliva and IgA detection in serum could be useful markers
for dengue diagnosis. In contrast, detection of IgA in saliva
and urine could also be a good marker but mainly for sec-
ondary cases.
IgG detection in saliva samples could be used to distin-
guish between a primary and a secondary dengue infection,
since they are only detected in saliva when the levels in
serum samples are high, characteristic of secondary cases.
Cuzzubbo et al.7 suggested the utility of saliva samples to
classify a secondary case. According to our results, study of
IgG in urine can also be employed to distinguish between a
primary and a secondary dengue infection.
Despite the fact that IgE antibodies have not been used
in dengue diagnosis, some authors have studied them in
dengue cases with different pictures or types of infection
as a possible prognostic marker in the development of
severe complications.11—13,16,35 We have included the
kinetics of the total and specific IgE antibodies to complete
the study.
Although there were no significant differences between
specific IgE antibody in primary and secondary dengue infec-
tions, the kinetics in secondary cases were different com-
pared with primary cases, and we observed an increase in OD
values for these secondary cases after day 4 of onset
(Figure 3). In a previous study of patients from the same
outbreak we found a significant difference between primary
and secondary infection with regard to IgE levels in samples
taken on the 5th to 7th days following onset.16
Higher levels of specific IgE observed in secondary cases
could be related to the findings of a direct relationship
between secondary dengue infection and the development
of a Th2 response36—39 favoring Ig isotype to switch from m to
e in B cells. The functional role of dengue-specific IgE in
secondary infection has not yet been explored, however it
could be associated with mast cell activation during dengue
infection inducing inflammatory mediators and cytokine
release.40 On the other hand, it would be interesting to study
the role of IgE in the protecting response or recovery mediat-
ing virus neutralization or antibody-dependent cell-mediated
cytotoxicity (ADCC) in dengue infection. The total IgE anti-
bodies were present at high levels in both primary and
secondary cases.In this study the kinetics of three serological markers (IgM,
IgA, and IgG) in serum, saliva, and urine samples from adult
patients with primary or secondary dengue 3 infection were
studied for the first time showing their behavior and useful-
ness in dengue virus diagnosis. The specific IgE could also play
a role as a serological marker in secondary infections.
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